BCR-0008

BCR-0008 is an orally active, small-molecule proteolysis-targeting chimera (PROTAC) designed to target and degrade signal transducer and activator of transcription 6 (STAT6). Developed by Baicreat, BCR-0008 is being investigated for the treatment of Th2-mediated inflammatory and autoimmune diseases, such as atopic dermatitis and asthma. STAT6 is a key transcription factor in the IL-4/IL-13 signaling pathway, acting as a master regulator of Th2-type immune responses. By selectively inducing the degradation of STAT6 at picomolar concentrations, BCR-0008 blocks downstream inflammatory cascades. Preclinical studies have demonstrated that BCR-0008 possesses high target selectivity, favorable pharmacokinetic properties, and robust efficacy in animal models of asthma and atopic dermatitis, with a wide therapeutic window.